SCHEMBL19393790

SCHEMBL19393790

Cc1ccc(CCNC(=N)NC(=N)N2CCCCC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 3/20 0.45
▸ RAB9A P51151 3/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ HTT P42858 1/20 0.45
▸ ALDH1A1 P00352 6/20 0.44
▸ TSHR P16473 1/20 0.44
▸ HRH3 Q9Y5N1 1/20 0.42
▸ HRH1 P35367 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ LMNA P02545 1/20 0.40
▸ TP53 P04637 1/20 0.40
▸ HPGD P15428 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14703383 0.86 MCHR1 (0.50) NPC1RAB9ASMN1; SMN2HTTALDH1A1
SCHEMBL14703253 0.86 TSHR (0.50) NPC1RAB9ASMN1; SMN2HTTALDH1A1
SCHEMBL17777313 0.86 MCHR1 (0.50) NPC1RAB9ASMN1; SMN2HTTALDH1A1
SCHEMBL14703240 0.86 MEN1 (0.46) NPC1RAB9ASMN1; SMN2HTTALDH1A1
SCHEMBL14703148 0.86 NPC1 (0.61) NPC1RAB9ASMN1; SMN2HTTALDH1A1
SCHEMBL14703378 0.86 NPC1 (0.61) NPC1RAB9ASMN1; SMN2HTTALDH1A1
Hydrochloric Acid SCHEMBL17668288 0.85 NPC1 (0.59) NPC1RAB9ASMN1; SMN2HTTALDH1A1
Hydrochloric Acid SCHEMBL17668293 0.85 NPC1 (0.59) NPC1RAB9ASMN1; SMN2HTTALDH1A1
SCHEMBL16692416 0.85 MCHR1 (0.48) NPC1RAB9ASMN1; SMN2HTTALDH1A1
SCHEMBL14703477 0.85 NPC1 (0.58) NPC1RAB9ASMN1; SMN2HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3222614-B1 BIGUANIDE COMPOUND AND USE THEREOF IMMUNOMET THERAPEUTICS INC (US) 2020-07-29 — — EP disclosed
EP-3222614-A2 BIGUANIDE COMPOUND AND USE THEREOF Immunomet Therapeutics Inc. (US) 2017-09-27 — — EP disclosed
Send feedback